Its unique biology, combined with insights from genetic deletion studies and small-molecule inhibitor development, has positioned FATP2 as both a mechanistic node and a therapeutic target in diabetes, liver disease, and cancer (1, 2). This evidence concerns the gene SLC27A2 and cancer.